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ABSTRACT
Aims To evaluate corneal hysteresis (CH) and intraocular
pressure (IOP) before and after IOP lowering with
prostaglandin analogue (PGA) therapy in medication-
naı ¨ve eyes.
Methods Inthisretrospective study,weincludedrecords
from 57 consecutive patients with open angle glaucoma
who were initiated on PGA. Patients underwent ocular
response analyser measurement with IOP assessment at
baseline (untreated) and at follow-up (treated).
Results Median follow-up time between IOP
measurements was 1.4 (range 0.4e13.5) months. IOP
was reduced by 3.2 mm Hg (18.8%) from 17.0 to
13.8 mm Hg (p<0.001). CH increased by 0.5 mm Hg
(5.2%) from 9.7 to 10.2 mm Hg (p¼0.02). Baseline CH
(but not baseline central corneal thickness) was
a signiﬁcant predictor of the magnitude of IOP reduction,
with patients in the lowest quartile of CH (mean
7.0 mm Hg) experiencing a 29.0% reduction in IOP while
those in the highest CH quartile (mean 11.9 mm Hg)
experienced a 7.6% reduction in IOP (p¼0.006). A
multivariate analysis controlling for baseline IOP
demonstrated that baseline CH independently predicted
the magnitude of IOP reduction with PGA therapy in both
per cent (ß¼3.5, p¼0.01) and absolute (ß¼0.6,
p¼0.02) terms.
Conclusion Although CH is inﬂuenced by IOP, baseline
CH is independently associated with the magnitude of
IOP reduction with PGA therapy.
INTRODUCTION
Glaucoma is a potentially blinding optic neurop-
athy that is estimated to affect 60.5 million people
worldwide by 2010.
1 Identiﬁed risk factors for
glaucoma include older age, lower central corneal
thickness (CCT), elevated intraocular pressure
(IOP), African-American race and Hispanic ethni-
city.
2e4 Since IOP is the only currently modiﬁable
risk factor for glaucoma, its accurate assessment
and successful reduction is crucial to treating the
disease.
The current clinical gold standard for measuring
IOP is Goldmann applanation tonometry (GAT).
5
Although it has been shown that GAT values are
elevated in eyes with thicker corneas, adjustment
of IOP for CCT has not been widely adopted due to
the variable magnitude of inﬂuence of CCTon GAT
and the risk of overcorrection.
6 In addition, there is
evidence from large clinical trials to suggest that
low CCT may be a risk factor for glaucoma inde-
pendent of its direct impact on GAT measurement
23 ;
this may result from either anatomical structure
and/or genetic tissue susceptibility.
27
One possible explanation for the failure of CCT
to account accurately for GAT measurement inac-
curacies is that resistance to corneal deformation
during applanation is more related to corneal
viscoelasticity or strength, rather than corneal
thickness.
8 Recently, the Ocular Response Analyzer
(ORA; Reichert, Corp., New York, USA) has been
used to attempt to adjust for viscoelastic corneal
properties when measuring IOP. This non-contact
tonometer measures several ocular properties
including corneal hysteresis (CH) and Goldmann-
correlated IOP (IOPg). CH is deﬁned as the differ-
ence between the air-jet pressure at inward and
outward applanation and is considered to be
a measure of corneal viscous dampening, and thus
the cornea’s resistance to deformation.
9e11 CH has
been shown be associated with progressive ﬁeld
worsening in primary open-angle glaucoma
(POAG), and lower CH was shown to be associated
with worse visual ﬁeld damage in patents with
asymmetric POAG.
91 2Several recent investigations
have demonstrated that IOPg may be a precise and
replicable alternative to GAT.
13e15 Accordingly, in
a study of CH and IOP, IOPg may be the preferable
measurement for IOP since both CH and IOPg are
obtained objectively and simultaneously from the
same machine.
In the Ocular Hypertension Treatment Study,
Brandt and colleagues reported that patients with
thicker corneas had smaller IOP reduction from
topical IOP-lowering medication.
16 Since CH may
capture different elements from CCT of the
cornea’s biomechanical nature, we sought to
determine if CH is also a signiﬁcant predictor of the
expected magnitude of IOP reduction with topical
IOP-lowering medication. Furthermore, since
increasing CH was previously reported following
surgical IOP lowering,
17 we sought to determine
whether IOP lowering with prostaglandin (PGA)
therapy is associated with increasing CH.
METHODS
The study was a retrospective cross-sectional study.
One hundred and thirty-eight consecutive patients
aged $18 years undergoing sequential CH
measurement at the authors’ practices in New York
City were considered for inclusion in this retro-
spective study. All patients had a clinical diagnosis
of POAG and had documented open angles by
gonioscopy within 2 years of inclusion. Patients
<18 years of age or with a history of corneal disease
or keratorefractive surgery were excluded. Consec-
utively evaluated eligible patients were included in
the study if they were naïve to ocular hypotensive
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Clinical sciencetherapy and were initiated on PGA monotherapy from an
untreated baseline. Eyes with a baseline IOPg >28 (n¼10) were
excluded from the study in order to eliminate leverage points
and limit the potential for regression to the mean on the study
results.
Included patients were seen at two separate visits where ORA
measurement and GAT were performed. In accordance with
clinic protocol, ORA measurements were performed until
a waveform score of 6.5 or better was obtained or until ﬁve
measurements were obtained per eye; the measurement with
the highest waveform score was retained. Patient records were
reviewed for demographic data and medication use. Baseline
CCT measurements obtained via ultrasound pachymetry (DGH
Technology, Exton, Pennsylvania, USA) were recorded from
patient charts. For both the baseline and follow-up visit, IOP
measured by GATand IOPg was recorded.
Statistical analyses were conducted using Stata 11/IC
(StataCorp LP, College Station, Texas, USA). IOPg was used as
the IOP measurement for all statistics presented, unless other-
wise speciﬁed. Among patients with two eligible eyes, the right
eye was chosen to conduct parametric statistical tests, including
paired t tests and ANOVA. The Bonferroni correction was used
to adjust for multiple pairwise comparisons where appropriate.
Generalised estimating equations were used to construct linear
models allowing for adjustment of inter-eye correlation among
individual patients. All statistical tests were two-sided, with
a 0.05 level of signiﬁcance.
RESULTS
We included 57 patients with POAG undergoing initial PGA
therapy from an untreated baseline. Patient characteristics are
presented in table 1. The mean and median intervals from
untreated baseline to PGA-treated follow-up examination were
2.262.5 months and 1.4 months, respectively (range 0.4e13.5
months). Over this duration, mean CH increased signiﬁcantly
(9.7e10.2 mm Hg; p¼0.02), while IOP decreased signiﬁcantly
(17.0e13.8 mm Hg, p<0.001).
We plotted the relationship between baseline and follow-up
IOP (ﬁgure 1), as well as between baseline CH and the decrease
in IOP between examinations (ﬁgure 2). A linear relationship
was observed between baseline CH and both the absolute
(r¼0.34, p¼0.01) and per cent change (r¼0.31, p¼0.02) in IOP
over this interval. Only a weak, non-signiﬁcant relationship was
observed between CCTand absolute (r¼0.12, p¼0.3) or per cent
(r¼0.17, p¼0.2) decrease in IOPg.
In order to determine whether the response to initiation of
topical therapy was dependent on baseline CH and/or CCT, we
examined the absolute and percentage decrease in IOP for each
quartile of CH and CCT (table 2). We observed a signiﬁcantly
smaller reduction in IOP among higher CH quintiles compared
with lower CH quartiles (ANOVA, p<0.01). No signiﬁcant
relationship was determined between CCT quartile and
response of IOP to topical therapy (ANOVA, p$0.4).
Patients with lower baseline CH also had moderately higher
baseline IOP (r¼ 0.32, p¼0.01). Accordingly, we sought to
determine whether the greater response to treatment among
patients with low CH occurred due to regression to the mean or
whether this relationship existed independently of baseline IOP.
Linear models were constructed and after adjusting for baseline
IOP, increasing baseline CH signiﬁcantly predicted a smaller
treatment response as measured by an absolute (ß¼0.6, 95% CI
0.1 to 1.1, p¼0.02) or per cent (ß¼3.5, 95% CI 0.8 to 6.3,
p¼0.01) change in IOP (table 3).
Table 1 Patient characteristics
Categories Value
Number of patients (number of eyes) 57 (109)
Age (years) 54.6615.4
Female (%) 45.0
Time between examinations (months) 2.262.5
CCT 542.8634.7




Values are mean6SD unless stated otherwise.
*p<0.02 for difference between baseline and follow-up measurements.
yp<0.001 for difference between baseline and follow-up measurements.
CCT, central corneal thickness; CH, corneal hysteresis; IOPg,
Goldmann-correlated intraocular pressure.
Figure 1 Baseline and follow-up intraocular pressure (IOP). A scatter
plot illustrates the relationship between baseline IOP and follow-up IOP
for each patient initiated on PGA therapy; the line y¼x is superimposed
to illustrate the relationship between pre- and post-treatment IOP for
each patient.
Figure 2 Intraocular pressure (IOP) reduction as a function of corneal
hysteresis (CH). A scatter plot illustrates the relationship between
baseline corneal hysteresis (CH) and the change in IOP following
initiation of prostaglandin analogue (PGA) therapy; the best-ﬁt line is
shown (r¼0.5).
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Clinical scienceTo conﬁrm the validity of our ﬁndings using the current
clinical standard GAT, we repeated the analyses using this vari-
able and found that GAT decreased signiﬁcantly with PGA
therapy (p<0.001). The magnitude of GAT reduction, as
measured by absolute (p¼0.02) and per cent change (p¼0.05),
also decreased with increasing CH. Moreover, we included
length of follow-up in the multivariable model containing
CH and IOP and found that it did not signiﬁcantly alter the
relationship between these variables (p>0.05).
DISCUSSION
In this investigation of patients with POAG experiencing IOP
reduction with primary PGA therapy, we conﬁrmed a depen-
dence of CH on IOP and demonstrated that baseline CH is
associated with the magnitude of IOP reduction. CH may be
a promising metric for predicting glaucoma progression.
9 The
present study adds to past investigations demonstrating that
CH may also be a valuable tool for assessing the expected
response of patients to topical PGA glaucoma therapy.
A number of prior studies have examined the association
between CH and glaucomatous visual ﬁeld or optic nerve ﬁnd-
ings.
9 18 19 In addition, investigations have indicated that eyes
with higher IOP have a lower CH and that therapeutic manip-
ulation of IOP may induce an inverse response in CH.
17 20 For
example, Sun and colleagues found that CH was signiﬁcantly
lower in eyes with chronic primary angle-closure glaucoma
compared with fellow-eyes and normal controls. Moreover, in
this prospective study, they found that following trabeculec-
tomy IOP decreased on average from 31.5 to 11.5 mm Hg and
that CH increased from 6.8 to 9.2 mm Hg over the same time
period.
17
With the apparent dependence of CH on IOP we expected to
observe regression of IOP towards the mean among patients
with low CH in this study. To address the issue of regression to
the mean, we adjusted for baseline IOP and determined that CH
remained signiﬁcantly associated with the magnitude of IOP
reduction from topical PGA therapy. Therefore, although CH is
generally lower in patients with higher IOP, independently of
this a lower CH may be predictive of a greater IOP reduction
from PGA therapy.
Given that a lower CH is also a risk factor for glaucoma
progression and that eyes with worse ﬁeld damage have lower
CH, the ﬁnding that patients with lower CH have a greater
response to PGA therapy paints a complex picture in the inte-
gration of IOP reduction and baseline risk factors.
9 12 One
possible explanation for this relationship may be that although
patients with lower CH are more responsive to PGA therapy,
they require a much greater IOP reduction than those with
higher CH in order to avoid progression. In addition, it is
possible that after initiation of therapy clinicians are satisﬁed
with the observed reduction in IOPand do not consider that IOP
may be underestimated in patients with lower CH.
In the present study, we were unable to replicate the ﬁnding
from the Ocular Hypertension Treatment Study that patients
with thicker corneas had smaller IOP responses to ocular
hypotensive medications including PGAs.
16 However, in that
study Brandt and colleagues found a difference in IOP reduction
of only 2.3 mm Hg (8.2%) between the top and bottom CCT
tercile for patients receiving PGA treatment.
16 Since we did
observe a trend towards patients with thicker corneas experi-
encing a smaller IOP reduction, we believe that the current
study may have been underpowered to the relatively small
impact of CCTon IOP response to topical therapy.
There are multiple hypotheses that may explain the differ-
ential response to PGA therapy as a function of CH seen in this
study. First, as Brandt and colleagues hypothesised regarding
patients with thick corneas,
16 it is possible that patients with
high CH comprise the 15e30% of glaucoma patients cited as
non-responders in drug trials.
21 22 It is also possible that IOP
measurement is affected by CH in such a manner that changes
in IOP are more difﬁcult to measure in eyes with high CH. Since
a higher CH corresponds to greater resistance to corneal defor-
mation, it is not surprising if any form of tonometry dependent
on corneal deformation or applantation may be impacted by
CH.
10 11 Finally, it is possible that CH correlates with
biostructural features of the cornea, such as collagen composi-
tion, that may shape the innate susceptibility of an eye to PGA
treatment. The possibility that CH correlates with such struc-
tural features of the eye is supported by research that has shown
a decrease of CH with ageing independent of changes in CCTor
IOP,
23 as well the ﬁnding that glaucoma patients with low CH
but not low CCT have greater backward bowing of the lamina
cribrosa in response to transient IOP elevation.
18
There are several limitations to the current study. Principally,
the investigation is limited by its retrospective nature.








(mm Hg) p Value
IOPg
(% change) p Value
CH
First quartile 7.0 e 19.4  5.8 ANOVA, p¼0.002  29.0 ANOVA, p¼0.008
Second quartile 8.8 e 17.4  3.7 0.1*  20.7 0.2*
Third quartile 10.0 e 16.5  3.7 0.2*  19.9 0.3*
Fourth quartile 11.9 e 15.9  1.1 0.001*  7.6 0.006*
CCT
First quartile e 497.3 16.4  3.9 ANOVA, p¼0.7  21.9 ANOVA, p¼0.4
Second quartile e 525.2 17.1  4.0 0.8*  23.1 0.8*
Third quartile e 549.1 16.9  3.1 1.0*  15.9 0.8*
Fourth quartile e 586.2 18.3  2.6 0.5*  13.4 0.5*
*Pairwise comparisons of change in IOPg compared with ﬁrst quartile CH or CCT; Bonferroni adjusted signiﬁcance level of 0.017.
CCT, central corneal thickness; CH, corneal hysteresis; IOP, intraocular pressure; IOPg, Goldmann-correlated intraocular pressure.
Table 3 Linear models of relationship between CH and IOPg response
to therapy
ß 95% CI p Value
Outcome: absolute IOPg decrease
Baseline CH 0.6 0.1 to 1.1 0.02
IOPg  0.5  0.8 to  0.3 <0.001
Outcome: per cent IOPg decrease
Baseline CH 3.5 0.8 to 6.3 0.01
IOPg  1.6  2.6 to  0.6 0.002
CH, corneal hysteresis; IOPg, Goldmann-correlated intraocular pressure.
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Clinical scienceAccordingly, we are unable to draw conclusions about causality
and the prospective impact of CH on IOP reduction. In addition,
we chose to employ IOPg to measure IOP in this study. Since
some prior studies have relied on other measurements of IOP,
particularly GAT, this may limit comparability across studies.
Nevertheless, we believe that this is a minor point since the
outcome of interest in this study was IOP change, not true IOP,
so any reproducible method of IOP measurement should provide
external validity. Finally, the study is limited by the lack of serial
IOP measurements. The authors acknowledge the improved
precision of serial IOP measurements; however, there is no
reason to believe that noise generated by a lack of serial
measurements would bias the study in a particular direction.
Acquisition of multiple IOP measurements was beyond the
scope of the current study, which is retrospective in nature and
exploited extant data from the standard clinical evaluation of
patients.
The present study adds to what is already known about the
usefulness of CH, demonstrating that this measure of corneal
biomechanics may be useful for predicting IOP change in
research and/or clinical settings. That CH is partially dependent
upon IOP deserves further consideration in determining whether
CH is truly an innate corneal property. Nevertheless, a prospec-
tive study with multiple treatment arms would be useful in
better deﬁning this relationship and clarifying its full implications
for improving patient care.
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